Literature DB >> 13517450

[Paroxysmal dyskinesia as the effect of megaphen].

M SCHONECKER.   

Abstract

Entities:  

Keywords:  CHLORPROMAZINE/injurious effects; MOVEMENT DISORDERS/etiology and pathogenesis

Mesh：

Substances：

Year:  1957        PMID： 13517450

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


× No keyword cloud information.
  10 in total

Review 1.  Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.

Authors:  Vladimir Lerner; Chanoch Miodownik
Journal:  Curr Psychiatry Rep       Date:  2011-08       Impact factor: 5.285

2.  [On speech loss after encephalitis].

Authors:  M MUMENTHALER; J WUNDERLI
Journal:  Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr       Date:  1960

3.  Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.

Authors:  Michel C F Shamy; Clement Zai; Vincenzo S Basile; James L Kennedy; Daniel J Müller; Mario Masellis
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-06-01

4.  Treatment Recommendations for Tardive Dyskinesia.

Authors:  Lucia Ricciardi; Tamara Pringsheim; Thomas R E Barnes; Davide Martino; David Gardner; Gary Remington; Donald Addington; Francesca Morgante; Norman Poole; Alan Carson; Mark Edwards
Journal:  Can J Psychiatry       Date:  2019-02-21       Impact factor: 4.356

5.  [Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia].

Authors:  D Hirjak; K M Kubera; S Bienentreu; P A Thomann; R C Wolf
Journal:  Nervenarzt       Date:  2019-05       Impact factor: 1.214

6.  An update on tardive dyskinesia: from phenomenology to treatment.

Authors:  Olga Waln; Joseph Jankovic
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2013-07-12

Review 7.  Treatment of neurolept-induced tardive dyskinesia.

Authors:  Stacey K Jankelowitz
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-16       Impact factor: 2.570

8.  Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic.

Authors:  Deepti Zutshi; Leslie J Cloud; Stewart A Factor
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-10-23

Review 9.  Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management.

Authors:  Venkatesh Sreeram; Shanila Shagufta; Faisal Kagadkar
Journal:  Cureus       Date:  2019-08-24

Review 10.  Movement disorders in psychiatric patients.

Authors:  Laura Perju-Dumbrava; Peter Kempster
Journal:  BMJ Neurol Open       Date:  2020-12-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.